<DOC>
	<DOCNO>NCT00716989</DOCNO>
	<brief_summary>The goal vaccination induce humoral ( antibody ) intracellular ( T lymphocyte ) responses . Various data show intradermal vaccination efficient intramuscular vaccination : humoral response statistically well intradermic vaccination , compare intramuscular vaccination , even target population old subject immunosuppressed patient</brief_summary>
	<brief_title>Pathophysiological Study Characteristics Changes Cutaneous Immune System After Intradermal Antigen Injections</brief_title>
	<detailed_description>Realisation 2 group healthy subject 2 intradermal injection 50 µl tuberculin + 2 intradermal injection 50 µl physiological serum . 5 biopsy perform 2 Tuberculin injection site , 2 physiological serum site 1 healthy skin site : - Group A : healthy young subject ( 18 40 year old ) : 18 subject - Sub-group A1 ( biopsy 30 minute injection ) : 6 subject - Sub-group A2 ( biopsy 4 hour injection ) : 6 subject - Sub-group A3 ( biopsy 72 hour injection ) : 6 subject - Group B : healthy old subject ( 60 75 year old ) : 18 subject - Sub-group B1 ( biopsy 30 minute injection ) : 6 subject - Sub-group B2 ( biopsy 4 hour injection ) : 6 subject - Sub-group B3 ( biopsy 72 hour injection ) : 6 subject Determination best time ( 30 minute , 4 hour 72 hour ) intradermal vaccination caracteristics group A B data analysis . From result , last group immunosuppressed patient perform : Group C 6 immunosuppressed patient ( 18 60 year old )</detailed_description>
	<criteria>Both gender eligible study . Female participant must use contraceptive method . Tuberculin skin test 1 15mm Participants must able understand sign Informed Consent , comply aspect protocol . Subjects register social security system health insurance cover First group : Healthy subject age 18 75 year 2 subgroup : 1840 6075 year old subject Second group : Patients kidney transplant longer 6 month immunosuppressive treatment Pregnant lactate woman . Previous allergic reaction tuberculin skin test Active skin disease test zone Patients clinically significant disease ( chronic , recurrent active ) Local systemic medication interact outcome measure . Patients deprive civic right , custody , care tutorial , judiciary administrative body . Patients relevant protection measure Patients critical medical situation Patients personal situation evaluate investigator unable give optimal participation study , could constitute risk patient Linguistic barrier psychological profile disable patient sign consent form Patient still exclusion period follow participation another clinical trial Patients earn 4500€ indemnity follow participation clinical trial last 12 month , include study For group 1 : Systemic corticotherapy immunosuppressive treatment within 2 week first visit within 2 week third visit biopsy . Systemic non antiinflammatory drug week first visit within 1 week third visit biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Cutaneous immune system</keyword>
	<keyword>innate immunity</keyword>
	<keyword>tuberculin skin test</keyword>
	<keyword>intradermal vaccination</keyword>
	<keyword>pathophysiology</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Immunosuppressed patient</keyword>
</DOC>